Use: Labeled indications
- JANUVIA ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE JANUVIA ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. JANUVIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (1) Limitations of Use: JANUVIA should not be used in patients with type 1 diabetes (1) JANUVIA has not been studied in patients with a history of pancreatitis.
(1, 5.1) Limitations of Use JANUVIA should not be used in patients with type 1 diabetes. JANUVIA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using JANUVIA. [See Warnings and Precautions (5.1).]
Contraindications
- History of serious hypersensitivity to sitagliptin (e.g., anaphylaxis, angioedema)
Contraindications (US label) US FDA label
4 CONTRAINDICATIONS History of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema. [See Warnings and Precautions (5.5); Adverse Reactions (6.2).] History of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema (5.5, 6.2)
Dosing: Adult
- Type 2 diabetes (glycemic control): 100 mg once daily; 50 mg if eGFR 30 to <45; 25 mg if eGFR <30 (including dialysis)
- The recommended dose of JANUVIA is 100 mg once daily. JANUVIA can be taken with or without food. (2.1)
- Dosage adjustment is recommended for patients with eGFR less than 45 mL/min/1.73 m². (2.2)
- Dosage Adjustment in Patients with Renal Impairment (2.2)
- eGFR greater than or equal to 30 mL/min/1.73 m² to less than 45 mL/min/1.73 m² eGFR less than 30 mL/min/1.73 m² (including patients with end stage renal disease [ESRD] on dialysis) 50 mg once daily 25 mg once daily
2.1 Recommended Dosing
2.1 Recommended Dosing The recommended dose of JANUVIA is 100 mg once daily. JANUVIA can be taken with or without food.
2.2 Recommendations for Use in Renal Impairment
2.2 Recommendations for Use in Renal Impairment Assess renal function prior to initiation of JANUVIA and periodically thereafter. For patients with an estimated glomerular filtration rate [eGFR] greater than or equal to 45 mL/min/1.73 m² to less than 90 mL/min/1.73 m², no dosage adjustment for JANUVIA is required. For patients with moderate renal impairment (eGFR greater than or equal to 30 mL/min/1.73 m² to less than 45 mL/min/1.73 m²), the dose of JANUVIA is 50 mg once daily.
For patients with severe renal impairment (eGFR less than 30 mL/min/1.73 m²) or with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis, the dose of JANUVIA is 25 mg once daily. JANUVIA may be administered without regard to the timing of dialysis.
Dosing: Altered kidney function
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor cleared by the kidneys. The US label lowers the dose to 50 mg daily at an estimated glomerular filtration rate (eGFR) of 30 to 44 and to 25 mg daily below 30 or on dialysis, without regard to dialysis timing.
Kidney function measure: Label uses eGFR (mL/min/1.73 m2).
Show full dosing details
- eGFR ≥60
- 100 mg once daily; no adjustment (label: eGFR ≥45).
- eGFR 30–59
- eGFR 45–59: 100 mg once daily. eGFR 30–44: 50 mg once daily (label).
- eGFR 15–29
- 25 mg once daily (label).
- eGFR <15 (not on dialysis)
- 25 mg once daily (label).
- Hemodialysis (intermittent)
- 25 mg once daily, without regard to dialysis timing (label).
- Peritoneal dialysis
- 25 mg once daily (label).
- CRRT
- No data in label.
- Dialyzable? Modestly: about 13.5% removed over a 3–4 hour hemodialysis session (label).
- Monitoring Assess kidney function before starting and periodically (label). Pancreatitis, hypoglycemia with sulfonylureas or insulin.
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Not established in children.
- eGFR 30–59
- Not established in children.
- eGFR 15–29
- Not established in children.
- eGFR <15 (not on dialysis)
- Not established in children.
- Hemodialysis (intermittent)
- Not established in children.
- Peritoneal dialysis
- Not established in children.
- CRRT
- Not established in children.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Renal impairment US FDA label
2.2 Recommendations for Use in Renal Impairment Assess renal function prior to initiation of JANUVIA and periodically thereafter. For patients with an estimated glomerular filtration rate [eGFR] greater than or equal to 45 mL/min/1.73 m² to less than 90 mL/min/1.73 m², no dosage adjustment for JANUVIA is required. For patients with moderate renal impairment (eGFR greater than or equal to 30 mL/min/1.73 m² to less than 45 mL/min/1.73 m²), the dose of JANUVIA is 50 mg once daily.
For patients with severe renal impairment (eGFR less than 30 mL/min/1.73 m²) or with end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis, the dose of JANUVIA is 25 mg once daily. JANUVIA may be administered without regard to the timing of dialysis.
8.6 Renal Impairment Sitagliptin is excreted by the kidney, and sitagliptin exposure is increased in patients with renal impairment. Lower dosages are recommended in patients with eGFR less than 45 mL/min/1.73 m² (moderate and severe renal impairment, as well as in ESRD patients requiring dialysis). [See Dosage and Administration (2.2); Clinical Pharmacology (12.3).]
Patients with Renal Impairment An approximately 2-fold increase in the plasma AUC of sitagliptin was observed in patients with moderate renal impairment with eGFR of 30 to less than 45 mL/min/1.73 m², and an approximately 4-fold increase was observed in patients with severe renal impairment, including patients with ESRD on hemodialysis, as compared to normal healthy control subjects.
Dosing: Pediatric
- Approved ages
- Safety and effectiveness not established in pediatric patients; pediatric trials (10–17 years) did not show efficacy (label).
- Usual dose
- Not established.
- Maximum dose
- Not applicable.
- Neonates
- Neonates: not established.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of JANUVIA have not been established in pediatric patients. Three 20-week double-blind, placebo-controlled studies each with 34-week extensions were conducted to evaluate the efficacy and safety of sitagliptin in 410 pediatric patients aged 10 to 17 years with inadequately controlled type 2 diabetes, with or without insulin therapy (HbA1c 6.5-10% for patients not on insulin, HbA1c 7-10% for patients on insulin).
At study entry, patients in study 1 were not treated with oral antihyperglycemic agents; patients in studies 2 and 3 were on maximally tolerated metformin therapy. The primary efficacy endpoint was the change from baseline in HbA1c after 20 weeks of therapy. The pre-specified primary efficacy analyses included data from study 1 and pooled data from studies 2 and 3, regardless of glycemic rescue or treatment discontinuation.
In both efficacy analyses, the effect of treatment with sitagliptin was not significantly different from placebo. In study 1, the mean baseline HbA1c was 7.5%, and 12% of patients were on insulin therapy. At week 20, the change from baseline in HbA1c in patients treated with JANUVIA (N=95) was 0.06% compared to 0.23% in patients treated with placebo (N=95), a difference of -0.17% (95% CI: -0.62, 0.28).
In studies 2 and 3, the mean baseline HbA1c was 8.0%, 15% of patients were on insulin and 72% were on metformin HCl doses of greater than 1,500 mg daily. At week 20, the change from baseline in HbA1c in patients treated with sitagliptin (N=107) was -0.23% compared to 0.09% in patients treated with placebo (N=113), a difference of -0.33% (95% CI: -0.70, 0.05).
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Of the total number of subjects (N=3884) in pre-approval clinical safety and efficacy studies of JANUVIA, 725 patients were 65 years and over, while 61 patients were 75 years and over. No overall differences in safety or effectiveness were observed between subjects 65 years and over and younger subjects.
While this and other reported clinical experience have not identified differences in responses between the elderly and younger patients, greater sensitivity of some older individuals cannot be ruled out. Because sitagliptin is substantially excreted by the kidney, and because aging can be associated with reduced renal function, renal function should be assessed more frequently in elderly patients [see Dosage and Administration (2.2), Warnings and Precautions (5.3)].
Dosage forms
Philippines
- Film-coated tablet: 25 mg, 50 mg, 100 mg
- Tablet: 25 mg, 50 mg, 100 mg
- Film c oated tablet: 50 mg
Registered products in the Philippines
216 products registered with the Food and Drug Administration (FDA) Philippines list Sitagliptin as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Sitaglipin (as phosphate) (1 product). Products registered under these spellings are included in the table and marked.
All registered products216
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AcanthaSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | Corbridge Group Phils., Inc.Importer: AMB HK Enterprises Inc. | DRP-12289-02 | Jul 8, 2027 | |
AcanthaSitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | Corbridge Group Phils., Inc.Importer: AMB HK Enterprises Inc. | DRP-12290-02 | Jul 8, 2027 | |
AdiviaSitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-7128 | Apr 20, 2031 | |
AdiviaSitagliptin (as phosphate monohydrate) | 25 mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-7127 | Apr 20, 2031 | |
AdiviaSitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-7129 | Apr 20, 2031 | |
AstaliptinSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10 (Box of 30's) | RxVAT-exempt | Sai Mirra Innopharm Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd. | DRP-8900-03 | Jun 8, 2030 | |
AstaliptinSitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Sai Mirra Innopharm Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd. | DRP-8901-03 | Feb 9, 2031 | |
Bsita 100Sitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Rhydburg Pharmaceuticals LimitedIndia | Genedrift Philippines OPC | DRP-16123 | Nov 6, 2029 | |
Bsita 50Sitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Rhydburg Pharmaceuticals Limited.India | Genedrift Philippines OPC | DRP-16122 | Nov 6, 2029 | |
100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | Rx | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-12289 | Jul 8, 2032 | ||
DiagliptinSitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-12290 | Jul 8, 2027 | |
Diaglow-100Sitagliptin (as phosphate monohydrate)` | 100 mg Film-Coated TabletAlu/Opaque PVC Foil Blister pack x 10's (Box of 100's) | RxVAT-exempt | Sunglow Lifescience Private LimitedIndia | Macropharma Corporation | DRP-17996 | Apr 21, 2031 | |
Diaglow-50Sitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/Opaque PVC Foil Blister pack x 10's (Box of 100's) | RxVAT-exempt | Sunglow Lifescience Private LimitedIndia | Macropharma Corporation | DRP-17997 | Apr 21, 2031 | |
DialiptinSitagliptin (as phosphate monohydrate) | 25 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | J.M. Tolmann Laboratories Inc.Metro Manila | — | DRP-11314 | Feb 24, 2032 | |
Dialiptin-100Sitagliptin (as phosphate) | 100mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Beximco Pharmaceuticals Ltd.bangladesh | Macropharma Corporation | DRP-13437 | Feb 17, 2028 | |
Dialiptin-25Sitagliptin (as phosphate) | 25mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Beximco Pharmaceuticals Ltd.bangladesh | Macropharma Corporation | DRP-13435 | Feb 17, 2028 | |
Dialiptin-50Sitagliptin (as phosphate) | 50mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Beximco Pharmaceuticals Ltd.Bangladesh | Macropharma Corporation | DRP-13436 | Feb 17, 2028 | |
Diasit 100Sitagliptin (as hydrochloride monohydrate) | 100 mg Film Coated TabletWhite opaque PVC/PVDC-Alu Blister pack x 10's (Box of 30's) | RxVAT-exempt | Aurobindo Pharma Limited, Formulation Unit - XVIndia | AAA Pharma, Inc. | DR-XY49065 | May 2, 2029 | |
Diasit 25Sitagliptin (as hydrochloride monohydrate) | 25 mg Film Coated TabletWhite opaque PVC/PVDC-Alu Blister pack x 10's (Box of 30's) | RxVAT-exempt | Aurobindo Pharma Limited, Formulation Unit - XVIndia | AAA Pharma, Inc. | DR-XY49067 | May 2, 2029 | |
Diasit 50Sitagliptin (as hydrochloride monohydrate) | 50 mg Film Coated TabletWhite opaque PVC/PVdC-Alu Blister pack x 10's (Box of 30's) | RxVAT-exempt | Aurobindo Pharma Limited, Formulation Unit - XVIndia | AAA Pharma, Inc. | DR-XY49066 | May 2, 2029 | |
DiasitzanSitagliptin | 100 mg Film-coated TabletAlu / PVC Opaque White Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Triple 888 Medical and Pharma Inc. | DRP-16597-01 | May 13, 2030 | |
Diasutin-100Sitagliptin (As Phosphate Monohydrate) | 100 mg Film Coated TabletAlu/Alu Blister Pack of 10's (Box of 30's) | RxVAT-exempt | Theon Pharmaceuticals LimitedIndia | Suhitas Pharmaceuticals, Inc. | DRP-12958 | Nov 9, 2027 | |
Diasutin-50Sitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s Box of 30’s | RxVAT-exempt | Theon Pharmaceuticals LimitedIndia | Suhitas Pharmaceuticals Inc. | DRP-8352 | Aug 28, 2029 | |
Diavel 100Sitagliptin (as phosphate) | 100mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's | RxVAT-exempt | Globela Pharma Private LimitedIndia | Amb HK Enterprises Inc.Importer: AMB HK Enterprises Inc. | DRP-13265 | Jan 18, 2028 | |
Diavel 50Sitagliptin (as phosphate) | 50mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 1 blister pack x 10 tablets) | RxVAT-exempt | Globela Pharma Private Limited.India | Amb HK Enterprises Inc.Importer: AMB HK Enterprises Inc. | DRP-13267 | Jan 18, 2028 | |
DiawellSitagliptin (As Phosphate) | 100mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-12548 | Aug 31, 2027 | |
DiawellSitagliptin (As Phosphate) | 50mg Film-Coated TabletAlu/Alu blister pack x 10's | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-12549 | Aug 31, 2027 | |
Gliden 100Sitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Rhydburg Pharmaceuticals LimitedIndia | Genedrift Philippines OPC | DRP-16142 | Nov 13, 2029 | |
Gliden 50Sitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Rhydburg Pharmaceuticals LimitedIndia | Genedrift Philippines OPC | DRP-16141 | Nov 13, 2029 | |
GlipgenSitagliptin | 100 mg Film-Coated TabletAlu/PVC Opaque White Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generisch Trading Inc. | DRP-16597-03 | May 13, 2030 | |
GliptadinSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10 (Box of 30's) | RxVAT-exempt | Sai Mirra Innopharm Pvt. Ltd.India | Medchoice Endocrine Group, Inc.Importer: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd. | DRP-8900-02 | Jun 8, 2030 | |
GliptadinSitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Sai Mirra Innopharm Pvt. Ltd.India | Medchoice Endocrine Group, Inc.Importer: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd. | DRP-8901-02 | Jun 8, 2030 | |
Gliptadin-100Sitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Medchoice Endocrine Group, Inc.Importer: Ambica International Corporation | DRP-9079-01 | Oct 31, 2030 | |
Gliptadin-50Sitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Medchoice Endocrine Group, Inc.Importer: Ambica International Corporation | DRP-9078-01 | Oct 31, 2030 | |
GliptalifeSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box ox of 30's) | RxVAT-exempt | Flourish PharmaIndia | Biophil Medical Equipment and Supplies Trading | DRP-16655 | Jun 10, 2030 | |
GliptalifeSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Innovative HealthcareIndia | Biophil Medical Equipment and Supplies Trading | DRP-19168 | Nov 11, 2031 | |
Gliptanova-100Sitagliptin (as phosphate monohydrate) | 100mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 60's and 100's) | RxVAT-exempt | Eskayef Pharmaceuticals LimitedBangladesh | Medinova Pharmaceutical Inc. | DRP-16382 | Feb 28, 2030 | |
Gliptanova-50Sitagliptin (as phosphate monohydrate) | 50 mg Film Coated TabletsAlu/Alu Blister Pack x 10's (Box of 30's, 60's and 100's) | RxVAT-exempt | Eskayef Pharmaceuticals LimitedBangladesh | Medinova Pharmaceutical Inc. | DRP-16383 | Feb 28, 2030 | |
GliptinsSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | TGP Pharma Inc.Importer: Ambica International Corporation | DRP-9079-03 | Oct 31, 2030 | |
GliptinsSitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | TGP Pharma Inc.Importer: Ambica International Corporation | DRP-9078-04 | Oct 31, 2030 | |
GlipzealSitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAlu-Alu Blister Pack x 10's Box of 30's | RxVAT-exempt | The ACME Laboratories Ltd.Bangladesh | Novocore Pharma Inc.Importer: Euro Generics International Phils., Inc. | DR-XY45081 | Feb 16, 2031 | |
GlipzealSitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | The ACME Laboratories Ltd.Bangladesh | Novocore Pharma Inc.Importer: Euro Generics International Phils., Inc. | DR-XY45080 | Feb 16, 2031 | |
GLUCADROP-100Sitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Bafna Pharmaceutical LimitedIndia | Vitalife Pharma & Medical Supply Inc.Importer: Medethix, Inc. | DRP-6382-03 | Oct 9, 2030 | |
Glucadrop-50Sitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Bafna Pharmaceuticals LimitedIndia | Vitalife Pharma & Medical Supply Inc.Importer: MedEthix, Inc. | DRP-6383-03 | Oct 9, 2030 | |
Glukex-100Sitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Medlink Pharma Phils., Inc.Importer: Ambica International Corporation | DRP-9079 | Oct 31, 2030 | |
Glukex-50Sitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Medlink Pharma Phils., Inc.Importer: Ambica International Corporation | DRP-9078 | Oct 31, 2030 | |
GluvianceSitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Rule Med Pharma Corp.Importer: Pharmakon Biotec, Inc. | DRP-13645-07 | Mar 22, 2028 | |
GlysiptinSitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu / White Opaque PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Totalcare Pharma Inc.Trader: Solvang Pharmaceuticals, Inc. | DRP-9441-02 | Apr 17, 2027 | |
GlyxeraSitagliptin (As Phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Beximco Pharmaceuticals Ltd.Bangladesh | Importer: Firmlink Pharma Phils., Co. | DR-XY47827 | Mar 17, 2027 | |
GlyxeraSitagliptin (As Phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Beximco Pharmaceuticals Ltd.Bangladesh | Firmlink Pharma Phils., Co. | DR-XY48383 | Sep 30, 2027 | |
Instadip 100Sitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Sun Pharmaceutical Industries LimitedIndia | Sun Pharma Philippines, Inc.Importer: Sun Pharma Philippines, Inc | DRP-12951 | Nov 8, 2027 | |
Instadip 25Sitagliptin (as phosphate) | 25 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Sun Pharmaceutical Industries LimitedIndia | Sun Pharma Philippines Inc. | DRP-13859 | May 11, 2028 | |
Instadip 50Sitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister pack of 10 Tablets (Box of 30's) | RxVAT-exempt | Sun Pharmaceutical Industries LimitedIndia | Sun Pharma Philippines, Inc. | DRP-12978 | Nov 11, 2027 | |
JanogenSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30 Tablets) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Alternative Platform Exchange, Inc.Importer: Pharmakon Biotec Inc. | DRP-13646-03 | Mar 22, 2028 | |
JanogenSitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's Tablets) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Alternative Platform Exchange, Inc.Importer: Pharmakon Biotec Inc. | DRP-13645-03 | Mar 22, 2028 | |
Januglip 100Sitagliptin (as phosphate) | 100 mg TabletAlu-PVC/PVDC Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | FSPC Pharmaceuticals Inc.Importer: AMB HK Enterprises Inc. | DRP-10623-02 | Oct 28, 2031 | |
JanuviaSitagliptin | 100 mg Film-Coated TabletIn a box of 4 PVDC/PE/PVC White opaque blister x 7’s (Box of 28's); In a box of 1 PVDC/PE/PVC White opaque blister x 7's (as Physician's Sample) (Box of 7's) | RxVAT-exempt | Organon Pharma (UK) LimitedUnited Kingdom | Importer: Merck Sharp & Dohme (I.A.) LLC | DRP-5944 | Jan 28, 2030 | |
JanuviaSitagliptin (as phosphate) | 25 mg Film-Coated TabletIn a box of 4 PVDC/PE/PVC White opaque blister x 7’s (Box of 28's) | RxVAT-exempt | Organon Pharma (UK) LimitedUnited Kingdom | Importer: Merck Sharp & Dohme (I.A.) LLC | DRP-5943 | Jan 28, 2030 | |
JANUVIASitagliptin | 50 mg Film-Coated TabletIn a box of 4 PVDC/PE/PVC White opaque blister x 7’s Box of 28's; In a box of 1 PVDC/PE/PVC White opaque blister x 7’s (as physician's sample) Box of 7's | RxVAT-exempt | Organon Pharma (UK) LimitedUnited Kingdom | Importer: Merck Sharp & Dohme (I.A.) LLC | DRP-5945 | Jan 28, 2030 | |
JanuvisSitagliptin (as phosphate) | 25 mg TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | AMB HK ENTERPRISES INC. | DRP-10625 | Oct 28, 2031 | |
JanuvisSitagliptin (as phosphate) | 50 mg TabletAlu-PVC/PVDC Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Oxpharm IncImporter: AMB HK Enterprises Inc. | DRP-10624-04 | Oct 28, 2031 | |
Januvit 100Sitagliptin (as monohydrate phosphate) | 100 mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box of 10's, 30's, and 60's) | RxVAT-exempt | SunGlow Lifesciences Private LimitedIndia | Despina Pharma Inc. | DRP-17956 | Apr 15, 2031 | |
Januvit 50Sitagliptin (as monohydrate phosphate) | 50 mg Film Coated TabletAlu/PVC Blister Pack x 10's (Box of 10's, 30's, and 60's) | RxVAT-exempt | SunGlow Lifesciences Private LimitedIndia | Despina Pharma Inc. | DRP-17955 | Apr 15, 2031 | |
JentinSitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 14's) | RxVAT-exempt | The Searle Company LimitedPakistan | Getz Bros. Philippines, Inc. | DR-XY49190 | Sep 13, 2029 | |
JentinSitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 14's) | RxVAT-exempt | The Searle Company LimitedPakistan | Getz Bros. Philippines, Inc. | DR-XY49189 | Sep 13, 2029 | |
Jestaglip 100Sitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 30's) | RxVAT-exempt | National Healthcare Pvt. Ltd.Nepal | Boon Pharma Corp.Importer: Orange Biotec Inc. | DRP-12919-02 | Oct 28, 2027 | |
Jestaglip 50Sitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | National Healthcare Pvt. Ltd.Nepal | Boon Pharma Corp.Importer: Orange Biotec Inc. | DRP-14689-03 | Nov 23, 2028 | |
KoztaSitagliptin (as hydrochloride monohydrate) | 100 mg Film-Coated TabletWhite Opaque PVC/PE/PVDC-Aluminum Blister Pack x 14's (Box of 28's) | RxVAT-exempt | Sag Manufacturing, S.L.U.Spain | UNILAB, Inc. | DRP-15217 | May 29, 2029 | |
KoztaSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10 (Box of 30's) | RxVAT-exempt | Sai Mirra Innopharm Pvt. Ltd.India | UNILAB, Inc.Importer: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd. | DRP-8900-04 | Jun 8, 2030 | |
KoztaSitagliptin (as hydrochloride monohydrate) | 25 mg Film-Coated TabletWhite Opaque PVC/PE/PVDC-Aluminum Blister Pack x 14's (Box of 28's) | RxVAT-exempt | Sag Manufacturing, S.L.U.Spain | UNILAB, Inc | DRP-16881 | Aug 29, 2030 | |
KoztaSitagliptin (as hydrochloride monohydrate) | 50 mg Film-Coated TabletWhite Opaque PVC/PE/PVDC-Aluminum Blister Pack x 14's (Box of 28's) | RxVAT-exempt | Sag Manufacturing, S.L.U.Spain | UNILAB, Inc | DRP-16880 | Aug 29, 2030 | |
KoztaSitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Sai Mirra Innopharm Pvt. Ltd.India | Unilab, Inc.Importer: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd. | DRP-8901-04 | Jun 8, 2030 | |
LupigliptinSitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Medspecialty, Inc.Trader: Solvang Pharmaceuticals, Inc. | DRP-7108-01 | Apr 20, 2031 | |
LupigliptinSitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Medspecialty, Inc.Trader: Solvang Pharmaceuticals, Inc. | DRP-9441-01 | Apr 17, 2027 | |
MedliptinSitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAlu/White Opaque PVDC Blister pack x 7's (Box of 28's) | RxVAT-exempt | Novagen Healthcare Private LimitedIndia | Medethix, Inc. | DRP-16354 | Feb 18, 2030 | |
MedliptinSitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/White Opaque PVDC Blister pack x 7's (Box of 28's) | RxVAT-exempt | Novagen Healthcare Private Limited.India | Medethix, Inc. | DRP-16355 | Feb 18, 2030 | |
NoneSitagliptin (as phosphate) | 100 mg Film Coated TabletAlu/PVC blister pack x 7's (Box of 4 blister packs x 7 tablets) | RxVAT-exempt | Novagen Healthcare LimitedIndia | Medethix, Inc. | DRP-18954 | Oct 6, 2031 | |
NoneSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Reta DrugImporter: Pharmakon Biotec Inc. | DRP-13646-05 | Mar 22, 2028 | |
NoneSitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAlu/White Opaque PVDC Blister pack x 7's (Box of 28's) | RxVAT-exempt | Novagen Healthcare Private LimitedIndia | Amethyst Global (Philippines) Inc.Importer: I.E. Medica, Inc. | DRP-16354-02 | Feb 18, 2030 | |
NoneSitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Bafna Pharmaceutical LimitedIndia | Actimed, Inc.Importer: Medethix, Inc. | DRP-6382-04 | Oct 9, 2030 | |
NoneSitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAluminum/Aluminum Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Watsons Personal Care Stores (Philippines), Inc.Trader: Innogen Pharmaceuticals, Inc. | DRP-7128-02 | Apr 20, 2031 | |
NoneSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10 (Box of 30's) | RxVAT-exempt | Sai Mirra Innopharm Pvt. Ltd.India | Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd. | DRP-8900 | Jun 8, 2030 | |
NoneSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10 (Box of 30's) | RxVAT-exempt | Sai Mirra Innopharm Pvt. Ltd.India | Ritemed Phils., Inc.Importer: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd. | DRP-8900-01 | Jun 8, 2030 | |
NoneSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-9079-05 | Oct 31, 2030 | |
NoneSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation | DRP-9079-06 | Oct 31, 2030 | |
NoneSitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletsAlu/Alu Blister Pack of 10's (Box of 30's) | RxVAT-exempt | National Healthcare Pvt. Ltd.Nepal | Reta DrugImporter: Orange Biotec Inc. | DRP-12919-01 | Oct 28, 2027 | |
NoneSitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 60's and 100's) | RxVAT-exempt | Eskayef Pharmaceuticals LimitedBangladesh | Skymed Pharma DistributorImporter: Medinova Pharmaceutical Inc. | DPR-16383-02 | Feb 28, 2030 | |
NoneSitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30 Tablets) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Reta DrugImporter: Pharmakon Biotec Inc. | DRP-13645-05 | Mar 22, 2028 | |
NoneSitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | National Healthcare Pvt. Ltd.Nepal | Reta DrugImporter: Orange Biotec Inc. | DRP-14689-01 | Nov 23, 2028 | |
NoneSitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Bafna Pharmaceuticals LimitedIndia | Actimed, Inc.Importer: Medethix, Inc. | DRP-6383-04 | Oct 9, 2030 | |
NoneSitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Sai Mirra Innopharm Pvt. Ltd.India | Ritemed Phils., Inc.Importer: Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd. | DRP-8901-01 | Jun 8, 2030 | |
NoneSitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals LimitedIndia | Reta DrugImporter: Ambica International Corporation | DRP-9031-02 | Aug 18, 2030 | |
NoneSitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | TGP Pharma Inc.Importer: Ambica International Corporation | DRP-9078-02 | Oct 31, 2030 | |
NoneSitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation | DRP-9078-03 | Oct 31, 2030 | |
NoneSitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | South Star DrugImporter: Ambica International Corporation | DRP-9078-08 | Oct 31, 2030 | |
philsitz-100Sitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-12289-01 | Jul 8, 2027 | |
Philsitz-50Sitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-12290-01 | Jul 8, 2027 | |
PremiliptinSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Premier Pharmaceuticals Marketing Corp.Importer: AMB HK Enterprises Inc. | DRP-13265-01 | Jan 18, 2028 | |
ProgliptinSitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Rhydburg Pharmaceutical LimitedIndia | Prebiotech Advanced Pharma Inc.Importer: Pharmastar Int'l Trading Corp. | DRP-8334-02 | Aug 15, 2029 | |
Si2normSitagliptin (As Phosphate Monohydrate) | 100 mg Film Coated TabletAlu/Alu Blister Pack of 10's (Box of 30's) | RxVAT-exempt | National Healthcare Pvt. Ltd.Nepal | Suhitas Pharmaceuticals, Inc. | DRP-12919 | Oct 28, 2027 | |
Si2normSitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | National Healthcare Pvt., Ltd.Nepal | Suhitas Pharmaceuticals Inc | DRP-14689 | Nov 23, 2028 | |
Silaptaen 100Sitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu-Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Rhydburg Pharmaceuticals LimitedIndia | Genedrift Philippines OPC | DRP-7316 | Sep 11, 2027 | |
Silaptaen 50Sitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu-Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Rhydburg Pharmaceuticals LimitedIndia | Genedrift Philippines OPC | DRP-7315 | Sep 11, 2027 | |
SitadinSitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAlu/White Opaque PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sydenham Laboratories, Inc.Philippines | Trader: Medchoice Endocrine Group, Inc. | DRP-13837 | Apr 27, 2028 | |
SitadinSitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/White Opaque PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sydenham Laboratories, Inc.Philippines | Trader: Medchoice Endocrine Group, Inc. | DRP-13761 | Apr 13, 2028 | |
Sitag-100Sitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's; Alu/Alu Blister Pack x 10's Box of 50's | RxVAT-exempt | Bafna Pharmaceutical LimitedIndia | MedEthix, Inc. | DRP-6382 | Oct 9, 2030 | |
Sitag-50Sitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 50's) | RxVAT-exempt | Bafna Pharmaceuticals LimitedIndia | MedEthix, Inc. | DRP-6383 | Oct 9, 2030 | |
SitagenSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's Tablets) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Alternative Platform Exchange, Inc.Importer: Pharmakon Biotec Inc. | DRP-13646-01 | Mar 22, 2028 | |
SitagenSitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30 Tablets) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Alternative Platform Exchange, Inc.Importer: Pharmakon Biotec Inc. | DRP-13645-01 | Mar 22, 2028 | |
Sitagli-100Sitagliptin | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s and 100’s) | RxVAT-exempt | Theon Pharmaceuticals LimitedIndia | Ambica International Corporation | DRP-11457 | Mar 16, 2032 | |
Sitagli-50Sitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s Box of 30’s | RxVAT-exempt | Theon Pharmaceuticals LimitedIndia | Ambica International Corporation | DRP-9031 | Aug 18, 2030 | |
SitagligoSitagliptin | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals LimitedIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-11457-01 | Mar 16, 2037 | |
SitagligoSitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals LimitedIndia | Applied Pharmaceutical Distribution Inc.Importer: Ambica International Corporation | DRP-9031-01 | Aug 18, 2030 | |
SitaglinexSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Beximco Pharmaceuticals Ltd.Bangladesh | Ambica International Corporation | DRP-12316 | Jul 13, 2032 | |
SitaglinexSitagliptin (As Phosphate) | 25 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Beximco Pharmaceuticals Ltd.Bangladesh | Ambica International Corporation | DRP-12318 | Jul 14, 2027 | |
SitaglinexSitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Beximco Pharmaceuticals Ltd.Bangladesh | Ambica International Corporation | DRP-12317 | Jul 14, 2027 | |
Sitaglisaph-100Sitagliptin (As Phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack X 10's (Box of 100's) | RxVAT-exempt | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc. | DRP-13116 | May 18, 2031 | |
Sitaglisaph-50Sitagliptin (As Phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc. | DRP-13117 | May 18, 2031 | |
SitaglizenSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Janamed CorporationImporter: Pharmakon Biotec Inc. | DRP-13646-04 | Mar 22, 2028 | |
SitaglizenSitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100 Tablets) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Janamed CorporationImporter: Pharmakon Biotec Inc. | DRP-13645-04 | Mar 22, 2028 | |
Sitaglux 100Sitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 60's and 100's) | RxVAT-exempt | Eskayef Pharmaceuticals LimitedBangladesh | GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutiucal Inc. | DRP-16382-01 | Feb 28, 2030 | |
Sitaglux 50Sitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 60's and 100's) | RxVAT-exempt | Eskayef Pharmaceuticals LimitedBangladesh | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-16383-01 | Feb 28, 2030 | |
SitagpinaSitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAlu/Alu blister pack x 10's Box of 30's | RxVAT-exempt | Rhydburg Pharmaceuticals LimitedIndia | Pharmastar Int'l Trading Corp. | DRP-8334 | Aug 15, 2029 | |
Sitagral-50Sitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu / Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals LimitedIndia | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-9031-03 | Aug 18, 2030 | |
Sitagram-100Sitagliptin | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s and 100’s) | RxVAT-exempt | Theon Pharmaceuticals LimitedIndia | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-11457-03 | Mar 16, 2032 | |
SitagrichSitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | National Healthcare Pvt. Ltd.Nepal | Medirich Pharma Distribution Corp.Importer: Orange Biotec Inc. | DRP-14689-02 | Nov 23, 2028 | |
Sitaguard 100Sitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 30's) | RxVAT-exempt | Theon Pharmaceuticals LimitedIndia | Preventia Healthcare Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-12958-01 | Nov 9, 2027 | |
Sitaguard 50Sitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals LimitedIndia | Preventia Healthcare Inc.Importer: Suhitas Pharmaceuticals Inc. | DRP-8352-01 | Aug 28, 2029 | |
SitakemSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu-Alu blister pack x 10's Box of 30's | RxVAT-exempt | Rhydburg Pharmaceutical Ltd.India | Alkem Laboratories CorporationImporter: Genedrift Philippines OPC | DRP-7316-01 | Sep 11, 2027 | |
SitakemSitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu-Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Rhydburg Pharmaceuticals Ltd.India | Alkem Laboratories CorporationImporter: Genedrift Philippines OPC | DRP-7315-01 | Sep 11, 2027 | |
Sitalia 100Sitagliptin (as monohydrate phosphate) | 100 mg Film Coated Tablet | RxVAT-exempt | Delta Pharma Ltd.Bangladesh | Biomed Pharma Inc. | DRP-17596 | Feb 6, 2031 | |
Sitallion 100Sitagliptin ( as phosphate monohydrate) | 100 mg Film-Coated TabletAlu/White Opaque PVDC Blister pack x 7's (Box of 28's) | RxVAT-exempt | Novagen Healthcare Private Limitedlridia | Amethyst Global (Philippines) Inc.Importer: I.E. Medica, Inc. | DRP-16354-01 | Feb 18, 2030 | |
Sitallion 50Sitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/White Opaque PVDC Blister pack x 7's (Box of 28's) | RxVAT-exempt | Novagen Healthcare Private LimitedIndia | Amethyst Global (Philippines) Inc.Importer: I.E. Medica, Inc. | DRP-16355-01 | Feb 18, 2030 | |
Sitamac 100Sitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAlu/Alu Cold Forming Blister Pack x 10 (Box of 30's) | RxVAT-exempt | Macleods Pharmaceuticals LimitedIndia | Macleods Pharmaceuticals Philippines, Inc. | DR-XY48544 | Jan 3, 2028 | |
Sitamac 50Sitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/Alu Cold Forming Blister Pack x 10 (Box of 30's) | RxVAT-exempt | Macleods Pharmaceuticals LimitedIndia | Macleods Pharmaceuticals Philippines, Inc. | DR-XY48543 | Jan 3, 2028 | |
SitaphilSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Phil Asia Pharma IncImporter: Ambica International Corporation | DRP-9079-02 | Oct 31, 2030 | |
SitaphilSitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Phil Asia Pharma IncImporter: Ambica International Corporation | DRP-9078-06 | Oct 31, 2030 | |
SitaproSitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Solvang Pharmaceuticals, Inc. | DRP-7108 | Apr 20, 2031 | |
SitaproSitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Transcend Phils., Inc. | DRP-9441 | Apr 17, 2027 | |
Sitarox-100Sitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's & 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Roxwester International Corp.Importer: Pharmakon Biotec Inc. | DRP-13646-08 | Mar 22, 2028 | |
Sitarox-50Sitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's & 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India 174101 | Roxwester International Corp.Importer: Pharmakon Biotec Inc. | DRP-13645-08 | Mar 22, 2028 | |
Sitastar-100Sitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Pharmastar Int'l Trading CorpImporter: Nelpa Lifesciences, Inc. | DRP-13116-01 | Dec 2, 2027 | |
Sitastar-50Sitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Pharmastar Int'l Trading CorpImporter: Nelpa Lifesciences, Inc. | DRP-13117-01 | Dec 2, 2027 | |
Sitathyst 50Sitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/White Opaque PVDC Blister pack x 7's (Box of 28's) | RxVAT-exempt | Novagen Healthcare Private LimitedIndia | Amethyst Global (Philippines) Inc.Importer: I.E. Medica, Inc. | DRP-16355-02 | Feb 18, 2030 | |
Sitatin 100Sitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Rhydburg Pharmaceuticals LimitedIndia | VE Pharma Inc.Trader: Vexxa Lifesciences Limited | DR-XY48592 | Jan 31, 2028 | |
Sitatin 50Sitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Rhydburg Pharmaceuticals Limited.India | VE Pharma Inc.Trader: Vexxa Lifesciences Limited | DR-XY48591 | Jan 31, 2028 | |
Sitavia 100Sitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) x 10's (Box of 30's) | RxVAT-exempt | Korea United Pharm., Int'l Jsc.Vietnam | United Douglas Pharm Philippines, Inc. | DR-XY48531 | Dec 14, 2027 | |
Sitavia 50Sitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Korea United Pharm., Int'l Jsc.Vietnam | United Douglas Pharm Philippines, Inc. | DR-XY48530 | Dec 14, 2027 | |
Sitazit 100Sitagliptin (As Hydrochloride) | 100 mg Film-Coated TabletPVC/PE/PVDC-Alu Blister Pack x 10's (Box of 3 blister packs x 10 tablets) | RxVAT-exempt | Hetero Labs Limited, Unit VIndia | Camber Pharmaceuticals, Inc. | DR-XY48546 | Dec 29, 2027 | |
Sitazit 25Sitagliptin (As Hydrochloride) | 25 mg Film-Coated TabletPVC/PE/PVDC-Alu Blister Pack x 10's (Box of 3 blister packs x 10 tablets) | RxVAT-exempt | Hetero Labs Limited, Unit VIndia | Camber Pharmaceuticals, Inc. | DR-XY48547 | Dec 29, 2027 | |
Sitazit 50Sitagliptin (As Hydrochloride) | 50 mg Film-Coated TabletPVC/PE/PVDC-Alu Blister Pack x 10's (Box of 3 blister packs x 10 tablets) | RxVAT-exempt | Hetero Labs Limited, Unit VIndia | Camber Pharmaceuticals, Inc. | DR-XY48548 | Dec 29, 2027 | |
SitazucaSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Mylan Laboratories LimitedIndia | Viatris Pharmaceuticals, Inc. | DR-XY49413 | Jun 10, 2030 | |
SitazucaSitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Mylan Laboratories LimitedIndia | Viatris Pharmaceuticals, Inc. | DR-XY49414 | Jun 10, 2030 | |
SitfarSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack of 3 x 10 Tablets (Box of 30 Tablets) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Pharmakon Biotec Inc. | DRP-13646 | Mar 22, 2028 | |
SitfarSitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30 Tablets) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Pharmakon Biotec Inc. | DRP-13645 | Mar 22, 2028 | |
Sitodol 100Sitagliptin (as phosphate monohydrate) | 100mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Rhydburg Pharmaceuticals LimitedIndia | Genedrift Philippines OPC | DRP-16131 | Nov 7, 2029 | |
Sitodol 50Sitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's and 30's) | RxVAT-exempt | Rhydburg Pharmaceuticals LimitedIndia | Genedrift Philippines OPC | DRP-16022 | Feb 11, 2030 | |
Sitplixin 100Sitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | HealthPrescription, Inc.Importer: Ambica International Corporation | DRP-9079-04 | Oct 31, 2030 | |
Sitplixin 50Sitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | HealthPrescription, Inc.Importer: Ambica International Corporation | DRP-9078-05 | Oct 31, 2030 | |
SitzeaSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-13646-06 | Mar 22, 2028 | |
SitzeaSitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-13645-06 | Mar 22, 2028 | |
Sunglip 100Sitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Rhydburg Pharmaceuticals LimitedIndia | Genedrift Philippines OPC | DRP-16107 | Oct 30, 2029 | |
Sunglip 50Sitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Rhydburg Pharmaceuticals Limited.India | Genedrift Philippines OPC | DRP-16108 | Oct 30, 2029 | |
SytaGet 50Sitagliptin (as monohydrate phosphate) | 50 mg Film-Coated TabletAlu/PVC Blister Pack x 14’s (Box of 28’s) | RxVAT-exempt | Sain Medicaments Pvt. Ltd.India | 2MG Incorporated | DRP-18138 | May 13, 2031 | |
TaglipinSitagliptin | 100 mg Film-Coated TabletAlu/PVC Opaque White Blister Pack x 10's (Box of 30's, 50's & 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-16597-02 | May 13, 2030 | |
TaglisydSitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAlu/PVDC Blister White Opaque x 10’s (Box of 100 tablets) | RxVAT-exempt | Sydenham Laboratories, Inc.Philippines | — | DRP-13854 | May 3, 2028 | |
TaglisydSitagliptin (as phosphate monohydrate) | 25 mg Film-Coated TabletAlu/White Opaque PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sydenham Laboratories, Inc.Philippines | — | DRP-13839 | Apr 27, 2028 | |
TaglisydSitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/White Opaque PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sydenham Laboratories, Inc.Philippines | — | DRP-13840 | Apr 27, 2028 | |
TiglipzaSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30 Tablets) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Lakeside Pharmaceuticals Phil., Inc.Importer: Pharmakon Biotec Inc. | DRP-13646-02 | Mar 22, 2028 | |
TiglipzaSitagliptin (as phosphate) | 50 mg Film-Coated Tablet | RxVAT-exempt | Magbro Healthcare Pvt. Ltd. | Lakeside Pharmaceuticals Phil., Inc.Importer: Pharmakon Biotec Inc. | DRP-13645-02 | Mar 22, 2028 | |
Torsit 100Sitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Torrent Pharmaceuticals Ltd.India | Torrent Pharma Philippines, Inc. | DR-XY48589 | Jan 30, 2028 | |
Torsit 100Sitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Torrent Pharma Philippines, Inc.Importer: Ambica International Corporation | DRP-9079-07 | Oct 31, 2030 | |
Torsit 25Sitagliptin (as phosphate monohydrate) | 25 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Torrent Pharmaceuticals Ltd.India | Torrent Pharma Philippines, Inc. | DR-XY48587 | Jan 30, 2028 | |
Torsit 50Sitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Torrent Pharmaceuticals Ltd.India | Torrent Pharma Philippines, Inc. | DR-XY48588 | Jan 30, 2028 | |
Torsit 50Sitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Torrent Pharma Philippines, Inc.Importer: Ambica International Corporation | DRP-9078-07 | Oct 31, 2030 | |
TreviaSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 14's) Alu/Alu Blister Pack x 1's (Physician sample) (Box of 1's) | RxVAT-exempt | Getz Pharma (Pvt.) Ltd.Pakistan | Getz Pharma (Phils.), Inc. | DR-XY47530 | Sep 9, 2030 | |
TreviaSitagliptin (as phosphate) | 50 mg Film-coated TabletAlu/Alu Blister Pack x 7's (Box of 14's) Alu/Alu Blister Pack x 1's (Physician sample) (Box of 1's) | RxVAT-exempt | Getz Pharma (Pvt.) Ltd.Pakistan | Getz Pharma (Phils.), Inc. | DR-XY47529 | Sep 9, 2030 | |
UnbrandedSitagliptin | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Theon Pharmaceuticals LimitedIndia | Reta DrugImporter: Ambica International Corporation | DRP-11457-02 | Mar 16, 2032 | |
UnbrandedSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Bulacan | Trader: Gamot Philippines, Inc. | DRP-12503 | Aug 26, 2032 | |
UnbrandedSitagliptin (as phosphate monohydrate) | 25 mg Film-Coated TabletAlu/alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Euro-Health Care Exponents, Inc. | DRP-11159 | Feb 8, 2037 | |
UnbrandedSitagliptin (as phosphate monohydrate) | 25 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Malolos Bulacan | Trader: Metz Pharmaceuticals, Inc. | DRP-11198 | Feb 11, 2032 | |
UnbrandedSitagliptin (as phosphate monohydrate) | 25 mg Film-Coated TabletAlu/Alu blister pack x 10's (box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Vamsler Phils. Incorporated | DRP-11202 | Feb 11, 2032 | |
UnbrandedSitagliptin (as phosphate monohydrate) | 25 mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Bulacan | Medspecialty, Inc.Trader: Innogen Pharmaceuticals, Inc. | DRP-7127-04 | Apr 20, 2031 | |
UnbrandedSitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Bulacan | Watsons Personal Care Stores (Philippines), Inc.Trader: Innogen Pharmaceuticals, Inc. | DRP-7129-02 | Apr 20, 2031 | |
UnbrandedSitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Bulacan | Medspecialty, Inc.Trader: Innogen Pharmaceuticals, Inc. | DRP-7129-05 | Apr 20, 2031 | |
UnbrandedSitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10 (Box of 30's) | RxVAT-exempt | Sai Mirra Innopharm Pvt. Ltd.India | Ambica International CorporationTrader: Neomi Pharmaceuticals Pvt. Ltd. | DRP-8901 | Jun 8, 2030 | |
VilantraSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Oxpharm Inc.Importer: AMB HK ENTERPRISES INC. | DRP-10623 | Oct 28, 2031 | |
VilantraSitagliptin (as phosphate) | 50 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Oxpharm Inc.Importer: AMB HK Enterprises Inc. | DRP-10624 | Oct 28, 2031 | |
VolreaSitagliptin (as phosphate monohydrate) | 100mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 30's ) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-12845 | Oct 18, 2027 | |
XeleviaSitagliptin (as phosphate) | 100 mg Film-Coated TabletIn a box of 4 PVDC/PE/PVC White opaque blister x 7’s (Box of 28's); In a box of 1 PVDC/PE/PVC White opaque blister x 7’s (as physician's sample) (Box of 7's) | RxVAT-exempt | Organon Pharma (UK) LimitedUnited Kingdom | Essex Pharmaceuticals, Inc.Importer: Merck Sharp & Dohme (I.A.) LLC | DRP-5944-01 | Jan 28, 2030 | |
XeleviaSitagliptin | 25 mg Film-Coated TabletIn a box of 4 PVDC/PE/PVC White opaque blister x 7’s (Box x 28's) | RxVAT-exempt | Organon Pharma (UK) LimitedUnited Kingdom | Essex Pharmaceuticals, Inc.Importer: Merck Sharp & Dohme (I.A.) LLC | DRP-5943-01 | Jan 28, 2030 | |
XeleviaSitagliptin | 50 mg Film-Coated TabletIn a box of 4 PVDC/PE/PVC White opaque blister x 7’s (Box of 28's); In a box of 1 PVDC/PE/PVC White opaque blister x 7’s (as physician's sample) (Box of 7's) | RxVAT-exempt | Organon Pharma (UK) LimitedUnited Kingdom | Essex Pharmaceuticals, Inc.Importer: Merck Sharp & Dohme (I.A.) LLC | DRP-5945-01 | Jan 28, 2030 | |
XglipSitagliptin (as phosphate monohydrate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Exemed PharmaceuticalsIndia | AMB HK Enterprises Inc | DRP-16996 | Sep 12, 2030 | |
XglipSitagliptin (as phosphate monohydrate) | 50 mg Film Coated TabletAlu/Alu blister Pack x 10's (Box of 100's) | RxVAT-exempt | Exemed PharmaceuticalsIndia | AMB HK Enterprises Inc. | DRP-17169 | Oct 10, 2030 | |
XiglipSitagliptin (as phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | The Cathay YSS Distributors Co., Inc.Importer: AMB HK Enterprises, Inc. | DRP-12289-03 | Jul 8, 2027 | |
XigtalptnSitagliptin | 100 mg Film-coated TabletAlu/PVC Opaque White Blister Pack x 10's (Box of 30's, 50's & 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-16597 | May 13, 2030 | |
Xigtalptn 25Sitagliptin (as Phosphate) | 25 mg Film-Coated TabletAlu/PVC Opaque White Blister Pack x 10's (Box of 30's, 50's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.,Philippines | — | DRP-19033 | Oct 19, 2031 | |
Xigtalptn 50Sitagliptin (as Phosphate) | 50 mg Film-Coated TabletAlu/PVC Opaque White Blister Pack x 10's (Box of 30's, 50's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.,Philippines | — | DRP-19027 | Oct 19, 2031 | |
Xordim-50Sitagliptin (as phosphate) | 50 mg Film Coated TabletAlu/Alu Blister pack of 10's (Box of 100's) | RxVAT-exempt | Innovative HealthcareIndia | ECE Pharmaceuticals, Inc.Importer: Biophil Medical Equipment And Supplies Trading | DRP-18404 | Jul 2, 2031 | |
Zincretin 100Sitagliptin (as phosphate) | 100 mg Film Coated TabletAlu-Alu blister pack x 10's (Box of 1 blister pack x 10 tablets physician sample; Box of 3 blister packs x 10 tablets) | RxVAT-exempt | Cadila Healthcare LimitedIndia | Zydus Healthcare Philippines Inc. | DRP-13290 | Jan 18, 2028 | |
Zincretin 50Sitagliptin | 50 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 10's (Box of 10's) as Physician's sample | RxVAT-exempt | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines Inc. | DRP-14085 | Jun 23, 2028 | |
Zita 100Sitagliptin | 100 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 10's (Box of 10's) as Physician's sample | RxVAT-exempt | Zydus Lifesciences LimitedIndia | Zydus Healthcare Philippines Inc. | DRP-14083 | Jun 23, 2028 | |
Zita 50Sitagliptin | 50 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 10's (Box of 10's) as Physician's sample | RxVAT-exempt | Zydus Lifesciences Limited.India | Zydus Healthcare Philippines Inc. | DRP-14084 | Jun 23, 2028 | |
ZytacareSitagliptin (as phosphate monohydrate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | National Healthcare Pvt. Ltd.Nepal | Medcare PharmaceuticalsImporter: Orange Biotec Inc. | DRP-14689-04 | Nov 23, 2028 | |
(no brand name)Sitagliptin (as Phosphate) | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Dr. Zen's Research, Inc. | DRP-12502 | Aug 26, 2027 | |
(no brand name)Sitagliptin (As Phosphate) | 25 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Beximco Pharmaceuticals Ltd.Bangladesh | Importer: Firmlink Pharma Phils., Co. | DR-XY47828 | Mar 17, 2027 | |
(no brand name)Sitagliptin (as phosphate monohydrate) | 25 mg Film-Coated TabletAlu/Alu blister pack x 10's (box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: D.B. Manix International, Inc. | DRP-11157 | Feb 8, 2027 | |
(no brand name)Sitagliptin (as phosphate monohydrate) | 25 mg Film-Coated TabletAlu/Alu blister pack x 10's (box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma, Incorporated | DRP-11158 | Feb 8, 2027 | |
(no brand name)Sitagliptin (as phosphate monohydrate) | 25 mg Film-Coated TabletAlu/Alu blister pack x 10's (box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Solvang Pharmaceuticals, Inc. | DRP-11161 | Feb 8, 2027 | |
(no brand name)Sitagliptin (as phosphate monohydrate) | 25 mg Film-Coated TabletAlu/Alu blister pack x 10's (box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Aldril Pharmaceuticals, Inc. | DRP-11197 | Feb 11, 2027 | |
(no brand name)Sitagliptin (as Phosphate) | 25 mg Film-Coated TabletAlu/Alu blister pack x 10's (box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Ultramed Pharma, Inc. | DRP-11199 | Feb 11, 2027 | |
(no brand name)Sitagliptin (as Phosphate monohydrate) | 25 mg Film-Coated TabletAlu/Alu blister pack x 10's (box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Vitalink Health Products, Inc. | DRP-11200 | Feb 11, 2027 | |
(no brand name)Sitagliptin (as Phosphate monohydrate) | 25 mg Film-Coated TabletAlu/Alu blister pack x 10's (box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DRP-11201 | Feb 11, 2027 | |
(no brand name)Sitagliptin (as phosphate monohydrate) | 25 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | — | DRP-14771 | Jan 2, 2029 | |
(no brand name)Sitagliptin (as phosphate monohydrate) | 50 mg Film C Oated TabletAlu/White Opaque PVDC Blister pack x 7's (Box of 28's) | RxVAT-exempt | Novagen Healthcare Private LimitedIndia | Medethix, Inc. | DRP-16356 | Feb 18, 2030 | |
(no brand name)Sitagliptin (as Phosphate) | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | — | DRP-12504 | Aug 26, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS 100 mg tablets are beige, round, film-coated tablets with "277" on one side. 50 mg tablets are light beige, round, film-coated tablets with "112" on one side. 25 mg tablets are pink, round, film-coated tablets with "221" on one side. Tablets: 100 mg, 50 mg, and 25 mg (3)
Warnings/Precautions
- Pancreatitis: There have been postmarketing reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. If pancreatitis is suspected, promptly discontinue JANUVIA. (5.1)
- Heart failure: Heart failure has been observed with two other members of the DPP-4 inhibitor class. Consider risks and benefits of JANUVIA in patients who have known risk factors for heart failure. Monitor patients for signs and symptoms. (5.2)
- Acute Renal Failure: Has been reported postmarketing, sometimes requiring dialysis. Assessment of renal function is recommended prior to initiating JANUVIA and periodically thereafter. (5.3)
- Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues: Increased risk of hypoglycemia when used in combination with insulin and/or an insulin secretagogue. Lower dose of insulin or insulin secretagogue may be required. (5.4, 7.1)
- Hypersensitivity Reactions: There have been postmarketing reports of serious allergic and hypersensitivity reactions in patients treated with JANUVIA such as anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome. Promptly stop JANUVIA, assess for other potential causes, institute appropriate monitoring and treatment. (5.5, 6.2)
- Severe and Disabling Arthralgia: Has been reported in patients taking DPP-4 inhibitors. Consider as a possible cause for …
5.1 Pancreatitis
5.1 Pancreatitis There have been postmarketing reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, in patients taking JANUVIA. After initiation of JANUVIA, patients should be observed carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected, JANUVIA should promptly be discontinued and appropriate management should be initiated.
It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using JANUVIA.
5.2 Heart Failure
5.2 Heart Failure An association between dipeptidyl peptidase-4 (DPP-4) inhibitor treatment and heart failure has been observed in cardiovascular outcomes trials for two other members of the DPP-4 inhibitor class. These trials evaluated patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease. Consider the risks and benefits of JANUVIA prior to initiating treatment in patients at risk for heart failure, such as those with a prior history of heart failure and a history of renal impairment, and observe these patients for signs and symptoms of heart failure during therapy.
Advise patients of the characteristic symptoms of heart failure and to immediately report such symptoms. If heart failure develops, evaluate and manage according to current standards of care and consider discontinuation of JANUVIA.
5.3 Acute Renal Failure
5.3 Acute Renal Failure There have been postmarketing reports of worsening renal function, including acute renal failure, sometimes requiring dialysis. A subset of these reports involved patients with renal impairment, some of whom were prescribed inappropriate doses of sitagliptin. A return to baseline levels of renal impairment has been observed with supportive treatment and discontinuation of potentially causative agents.
Consideration can be given to cautiously reinitiating JANUVIA if another etiology is deemed likely to have precipitated the acute worsening of renal function. Assessment of renal function is recommended prior to initiating JANUVIA and periodically thereafter. A dosage adjustment is recommended in patients with moderate or severe renal impairment and in patients with ESRD requiring hemodialysis or peritoneal dialysis. [See Dosage and Administration (2.2); Use in Specific Populations (8.6).]
5.4 Hypoglycemia with Concomitant Use with Insulin
5.4 Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues When JANUVIA was used in combination with insulin or insulin secretagogues (e.g., sulfonylurea), medications known to cause hypoglycemia, the incidence of hypoglycemia was increased over that of placebo used in combination with a sulfonylurea or with insulin. [See Adverse Reactions (6.1).] Therefore, a lower dose of sulfonylurea or insulin may be required to reduce the risk of hypoglycemia. [See Drug Interactions (7.1).]
5.5 Hypersensitivity Reactions
5.5 Hypersensitivity Reactions There have been postmarketing reports of serious hypersensitivity reactions in patients treated with JANUVIA. These reactions include anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome. Onset of these reactions occurred within the first 3 months after initiation of treatment with JANUVIA, with some reports occurring after the first dose.
If a hypersensitivity reaction is suspected, discontinue JANUVIA, assess for other potential causes for the event, and institute alternative treatment for diabetes. [See Adverse Reactions (6.2).] Angioedema has also been reported with other DPP-4 inhibitors. Use caution in a patient with a history of angioedema with another DPP-4 inhibitor because it is unknown whether such patients will be predisposed to angioedema with JANUVIA.
5.6 Severe and Disabling Arthralgia
5.6 Severe and Disabling Arthralgia There have been postmarketing reports of severe and disabling arthralgia in patients taking DPP-4 inhibitors. The time to onset of symptoms following initiation of drug therapy varied from one day to years. Patients experienced relief of symptoms upon discontinuation of the medication.
A subset of patients experienced a recurrence of symptoms when restarting the same drug or a different DPP-4 inhibitor. Consider DPP-4 inhibitors as a possible cause for severe joint pain and discontinue drug if appropriate.
5.7 Bullous Pemphigoid
5.7 Bullous Pemphigoid Postmarketing cases of bullous pemphigoid requiring hospitalization have been reported with DPP-4 inhibitor use. In reported cases, patients typically recovered with topical or systemic immunosuppressive treatment and discontinuation of the DPP-4 inhibitor. Tell patients to report development of blisters or erosions while receiving JANUVIA.
If bullous pemphigoid is suspected, JANUVIA should be discontinued and referral to a dermatologist should be considered for diagnosis and appropriate treatment.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Insulin or insulin secretagogues (e.g., sulfonylureas) | Adjust or monitor | More hypoglycemia. | Lower insulin or secretagogue doses may be needed. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedDrug interactions (US label) US FDA label
7 DRUG INTERACTIONS 7.1 Insulin Secretagogues or Insulin Coadministration of JANUVIA with an insulin secretagogue (e.g., sulfonylurea) or insulin may require lower doses of the insulin secretagogue or insulin to reduce the risk of hypoglycemia. [See Warnings and Precautions (5.4).]
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
In vitro studies indicated that the primary enzyme responsible for the limited metabolism of sitagliptin was CYP3A4, with contribution from CYP2C8.
Sitagliptin is also a substrate of P-glycoprotein (P-gp), which may also be involved in mediating the renal elimination of sitagliptin.
However, cyclosporine, a P-gp inhibitor, did not reduce the renal clearance of sitagliptin.
Drug Interaction Studies In Vitro Assessment of Drug Interactions Sitagliptin is not an inhibitor of CYP isozymes CYP3A4, 2C8, 2C9, 2D6, 1A2, 2C19 or 2B6, and is not an inducer of CYP3A4.
Sitagliptin is a P-gp substrate, but does not inhibit P-gp mediated transport of digoxin.
In Vivo Assessment of Drug Interactions Effects of Sitagliptin on Other Drugs In clinical studies, sitagliptin did not meaningfully alter the pharmacokinetics of metformin, glyburide, simvastatin, rosiglitazone, digoxin, warfarin, or an oral contraceptive (ethinyl estradiol and norethindrone) (Table 4), providing in vivo evidence of a low propensity for causing drug interactions with substrates of CYP3A4, CYP2C8, CYP2C9, P-gp, and organic cationic transporter (OCT).
Adverse reactions
Common
- Upper respiratory tract infection, nasopharyngitis, headache (≥5% and more than placebo)
Serious
- Acute pancreatitis
- Heart failure (DPP-4 inhibitor association)
- Acute renal failure, sometimes requiring dialysis (postmarketing)
- Hypoglycemia with insulin or secretagogues
- Serious hypersensitivity (anaphylaxis, angioedema, exfoliative skin reactions)
- Severe and disabling arthralgia
- Bullous pemphigoid
- The following adverse reactions are also discussed elsewhere in the labeling: Pancreatitis [see Warnings and Precautions (5.1)] Heart Failure [see Warnings and Precautions (5.2)] Acute Renal Failure [see Warnings and Precautions (5.3)] Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues [see Warnings and Precautions (5.4)] Hypersensitivity Reactions [see Warnings and Precautions (5.5)] Severe and Disabling Arthralgia [see Warnings and Precautions (5.6)] Bullous Pemphigoid [see Warnings and Precautions (5.7)] Adverse reactions reported in ≥5% of patients treated with JANUVIA and more commonly than in patients treated with placebo are: upper respiratory tract infection, nasopharyngitis and headache. In the add-on to sulfonylurea and add-on to insulin studies, hypoglycemia was also more commonly reported in patients treated with JANUVIA compared to placebo. (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme LLC at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In controlled clinical studies as both monotherapy and combination therapy with metformin, pioglitazone, or rosiglitazone and metformin, the overall incidence of adverse reactions, hypoglycemia, and discontinuation of therapy due to clinical adverse reactions with JANUVIA were similar to placebo.
In combination with glimepiride, with or without metformin, the overall incidence of clinical adverse reactions with JANUVIA was higher than with placebo, in part related to a higher incidence of hypoglycemia (see Table 3); the incidence of discontinuation due to clinical adverse reactions was similar to placebo. Two placebo-controlled monotherapy studies, one of 18- and one of 24-week duration, included patients treated with JANUVIA 100 mg daily, JANUVIA 200 mg daily, and placebo.
Five placebo-controlled add-on combination therapy studies were also conducted: one with metformin; one with pioglitazone; one with metformin and rosiglitazone; one with glimepiride (with or without metformin); and one with insulin (with or without metformin). In these trials, patients with inadequate glycemic control on a stable dose of the background therapy were randomized to add-on therapy with JANUVIA 100 mg daily or placebo.
The adverse reactions, excluding hypoglycemia, reported regardless of investigator assessment of causality in ≥5% of patients treated with JANUVIA 100 mg daily and more commonly than in patients treated with placebo, are shown in Table 1 for the clinical trials of at least 18 weeks duration. Incidences of hypoglycemia are shown in Table 3.
Table 1: Placebo-Controlled Clinical Studies of JANUVIA Monotherapy or Add-on Combination Therapy with Pioglitazone, Metformin + Rosiglitazone, or Glimepiride +/- Metformin: Adverse Reactions (Excluding Hypoglycemia) Reported in ≥5% of Patients and More Commonly than in Patients Given Placebo, Regardless of Investigator Assessment of Causality Intent-to-treat population Number of Patients (%) Monotherapy (18 or 24 weeks) JANUVIA 100 mg Placebo N = 443 N = 363 Nasopharyngitis 23 (5.2) 12 (3.3) Combination with Pioglitazone (24 weeks) JANUVIA 100 mg + Pioglitazone Placebo + Pioglitazone N = 175 N = 178 Upper Respiratory Tract Infection 11 (6.3) 6 (3.4) Headache 9 (5.1) 7 (3.9) Combination with Metformin + Rosiglitazone (18 weeks) JANUVIA 100 mg + Metformin + Rosiglitazone Placebo + Metformin + Rosiglitazone N = 181 N = 97 Upper Respiratory Tract Infection 10 (5.5) 5 (5.2) Nasopharyngitis 11 (6.1) 4 (4.1) Combination with Glimepiride (+/- Metformin) (24 weeks) JANUVIA 100 mg + Glimepiride (+/- Metformin) Placebo + Glimepiride (+/- Metformin) N = 222 N = 219 Nasopharyngitis 14 (6.3) 10 (4.6) Headache 13 (5.9) 5 (2.3) In the 24-week study of patients receiving JANUVIA as add-on combination therapy with metformin, there were no adverse reactions reported regardless of investigator assessment of causality in ≥5% of patients and more commonly than in patients given placebo. In the 24-week study of patients receiving JANUVIA as add-on therapy to insulin (with or without metformin), there were no adverse reactions reported regardless of investigator assessment of causality in ≥5% of patients and more commonly than in patients given placebo, except for hypoglycemia (see Table 3).
In the study of JANUVIA as add-on combination therapy with metformin and rosiglitazone (Table 1), through Week 54 the adverse reactions reported regardless of investigator assessment of causality in ≥5% of patients treated with JANUVIA and more commonly than in patients treated with placebo were: upper respiratory tract infection (JANUVIA, 15.5%; placebo, 6.2%), nasopharyngitis (11.0%, 9.3%), peripheral edema (8.3%, 5.2%), and headache (5.5%, 4.1%). In a pooled analysis of the two monotherapy studies, the add-on to metformin study, and the add-on to pioglitazone study, the incidence of selected gastrointestinal adverse reactions in patients treated with JANUVIA was as follows: abdominal pain (JANUVIA 100 mg, 2.3%; placebo, 2.1%), nausea (1.4%, 0.6%), and diarrhea (3.0%, 2.3%).
In an additional, 24-week, placebo-controlled factorial study of initial therapy with sitagliptin in combination with metformin, the adverse reactions reported (regardless of investigator assessment of causality) in ≥5% of patients are shown in Table 2. Table 2: Initial Therapy with Combination of Sitagliptin and Metformin: Adverse Reactions Reported (Regardless of Investigator Assessment of Causality) in ≥5% of Patients Receiving Combination Therapy (and Greater than in Patients Receiving Metformin alone, Sitagliptin alone, and Placebo) Intent-to-treat population.
Number of Patients (%) Placebo Sitagliptin (JANUVIA) 100 mg QD Metformin HCl 500 or 1000 mg bid Data pooled for the patients given the lower and higher doses of metformin. Sitagliptin 50 mg bid + Metformin HCl 500 or 1000 mg bid N = 176 N = 179 N = 364 N = 372 Upper Respiratory Infection 9 (5.1) 8 (4.5) 19 (5.2) 23 (6.2) Headache 5 (2.8) 2 (1.1) 14 (3.8) 22 (5.9) In a 24-week study of initial therapy with JANUVIA in combination with pioglitazone, there were no adverse reactions reported (regardless of investigator assessment of causality) in ≥5% of patients and more commonly than in patients given pioglitazone alone.
No clinically meaningful changes in vital signs or in ECG (including in QTc interval) were observed in patients treated with JANUVIA. In a pooled analysis of 19 double-blind clinical trials that included data from 10,246 patients randomized to receive sitagliptin 100 mg/day (N=5429) or corresponding (active or placebo) control (N=4817), the incidence of acute pancreatitis was 0.1 per 100 patient-years in each group (4 patients with an event in 4708 patient-years for sitagliptin and 4 patients with an event in 3942 patient-years for control).
Hypoglycemia In the above studies (N=9), adverse reactions of hypoglycemia were based on all reports of symptomatic hypoglycemia. A concurrent blood glucose measurement was not required although most (74%) reports of hypoglycemia were accompanied by a blood glucose measurement ≤70 mg/dL. When JANUVIA was coadministered with a sulfonylurea or with insulin, the percentage of patients with at least one adverse reaction of hypoglycemia was higher than in the corresponding placebo group (Table 3).
Table 3: Incidence and Rate of Hypoglycemia Adverse reactions of hypoglycemia were based on all reports of symptomatic hypoglycemia; a concurrent glucose measurement was not required; intent-to-treat population. in Placebo-Controlled Clinical Studies when JANUVIA was used as Add-On Therapy to Glimepiride (with or without Metformin) or Insulin (with or without Metformin), Regardless of Investigator Assessment of Causality Add-On to Glimepiride (+/- Metformin) (24 weeks) JANUVIA 100 mg + Glimepiride (+/- Metformin) Placebo + Glimepiride (+/- Metformin) N = 222 N = 219 Overall (%) 27 (12.2) 4 (1.8) Rate (episodes/patient-year) Based on total number of events (i.e., a single patient may have had multiple events). 0.59 0.24 Severe (%) Severe events of hypoglycemia were defined as those events requiring medical assistance or exhibiting depressed level/loss of consciousness or seizure. 0 (0.0) 0 (0.0) Add-On to Insulin (+/- Metformin) (24 weeks) JANUVIA 100 mg + Insulin (+/- Metformin) Placebo + Insulin (+/- Metformin) N = 322 N = 319 Overall (%) 50 (15.5) 25 (7.8) Rate (episodes/patient-year) 1.06 0.51 Severe (%) 2 (0.6) 1 (0.3) In a pooled analysis of the two monotherapy studies, the add-on to metformin study, and the add-on to pioglitazone study, the overall incidence of adverse reactions of hypoglycemia was 1.2% in patients treated with JANUVIA 100 mg and 0.9% in patients treated with placebo. In the study of JANUVIA as add-on combination therapy with metformin and rosiglitazone, the overall incidence of hypoglycemia was 2.2% in patients given add-on JANUVIA and 0.0% in patients given add-on placebo through Week 18.
Through Week 54, the overall incidence of hypoglycemia was 3.9% in patients given add-on JANUVIA and 1.0% in patients given add-on placebo. In the 24-week, placebo-controlled factorial study of initial therapy with JANUVIA in combination with metformin, the incidence of hypoglycemia was 0.6% in patients given placebo, 0.6% in patients given JANUVIA alone, 0.8% in patients given metformin alone, and 1.6% in patients given JANUVIA in combination with metformin.
In the study of JANUVIA as initial therapy with pioglitazone, one patient taking JANUVIA experienced a severe episode of hypoglycemia. There were no severe hypoglycemia episodes reported in other studies except in the study involving coadministration with insulin. In an additional, 30-week placebo-controlled, study of patients with type 2 diabetes inadequately controlled with metformin comparing the maintenance of sitagliptin 100 mg versus withdrawal of sitagliptin when initiating basal insulin therapy, the event rate and incidence of documented symptomatic hypoglycemia (blood glucose measurement ≤70 mg/dL) did not differ between the sitagliptin and placebo groups.
Laboratory Tests Across clinical studies, the incidence of laboratory adverse reactions was similar in patients treated with JANUVIA 100 mg compared to patients treated with placebo. A small increase in white blood cell count (WBC) was observed due to an increase in neutrophils. This increase in WBC (of approximately 200 cells/microL vs placebo, in four pooled placebo-controlled clinical studies, with a mean baseline WBC count of approximately 6600 cells/microL) is not considered to be clinically relevant.
In a 12-week study of 91 patients with chronic renal insufficiency, 37 patients with moderate renal insufficiency were randomized to JANUVIA 50 mg daily, while 14 patients with the same magnitude of renal impairment were randomized to placebo. Mean (SE) increases in serum creatinine were observed in patients treated with JANUVIA [0.12 mg/dL (0.04)] and in patients treated with placebo [0.07 mg/dL (0.07)].
The clinical significance of this added increase in serum creatinine relative to placebo is not known.
6.2 Postmarketing Experience
6.2 Postmarketing Experience Additional adverse reactions have been identified during postapproval use of JANUVIA as monotherapy and/or in combination with other antihyperglycemic agents. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria, cutaneous vasculitis, and exfoliative skin conditions including Stevens-Johnson syndrome; hepatic enzyme elevations; acute pancreatitis, including fatal and non-fatal hemorrhagic and necrotizing pancreatitis [see Indications and Usage (1)]; worsening renal function, including acute renal failure (sometimes requiring dialysis), and tubulointerstitial nephritis; severe and disabling arthralgia; bullous pemphigoid; constipation; vomiting; headache; myalgia; pain in extremity; back pain; pruritus; mouth ulceration; stomatitis; rhabdomyolysis.
Adverse reaction frequency tables (US label) US FDA label
| Number of Patients (%) | ||
| Monotherapy (18 or 24 weeks) | JANUVIA 100 mg | Placebo |
| N = 443 | N = 363 | |
| Nasopharyngitis | 23 (5.2) | 12 (3.3) |
| Combination with Pioglitazone (24 weeks) | JANUVIA 100 mg +Pioglitazone | Placebo +Pioglitazone |
| N = 175 | N = 178 | |
| Upper Respiratory Tract Infection | 11 (6.3) | 6 (3.4) |
| Headache | 9 (5.1) | 7 (3.9) |
| Combination with Metformin + Rosiglitazone (18 weeks) | JANUVIA 100 mg + Metformin + Rosiglitazone | Placebo + Metformin + Rosiglitazone |
| N = 181 | N = 97 | |
| Upper Respiratory Tract Infection | 10 (5.5) | 5 (5.2) |
| Nasopharyngitis | 11 (6.1) | 4 (4.1) |
| Combination with Glimepiride (+/- Metformin) (24 weeks) | JANUVIA 100 mg + Glimepiride (+/- Metformin) | Placebo+ Glimepiride(+/- Metformin) |
| N = 222 | N = 219 | |
| Nasopharyngitis | 14 (6.3) | 10 (4.6) |
| Headache | 13 (5.9) | 5 (2.3) |
| Number of Patients (%) | ||||
| Placebo | Sitagliptin (JANUVIA) 100 mg QD | Metformin HCl500 or 1000 mg bidData pooled for the patients given the lower and higher doses of metformin. | Sitagliptin50 mg bid +Metformin HCl500 or 1000 mg bid | |
| N = 176 | N = 179 | N = 364 | N = 372 | |
| Upper Respiratory Infection | 9 (5.1) | 8 (4.5) | 19 (5.2) | 23 (6.2) |
| Headache | 5 (2.8) | 2 (1.1) | 14 (3.8) | 22 (5.9) |
| Add-On to Glimepiride (+/- Metformin) (24 weeks) | JANUVIA 100 mg+ Glimepiride(+/- Metformin) | Placebo+ Glimepiride(+/- Metformin) |
| N = 222 | N = 219 | |
| Overall (%) | 27 (12.2) | 4 (1.8) |
| Rate (episodes/patient-year)Based on total number of events (i.e., a single patient may have had multiple events). | 0.59 | 0.24 |
| Severe (%)Severe events of hypoglycemia were defined as those events requiring medical assistance or exhibiting depressed level/loss of consciousness or seizure. | 0 (0.0) | 0 (0.0) |
| Add-On to Insulin (+/- Metformin) (24 weeks) | JANUVIA 100 mg+ Insulin(+/- Metformin) | Placebo+ Insulin(+/- Metformin) |
| N = 322 | N = 319 | |
| Overall (%) | 50 (15.5) | 25 (7.8) |
| Rate (episodes/patient-year) | 1.06 | 0.51 |
| Severe (%) | 2 (0.6) | 1 (0.3) |
Monitoring parameters
- Assess kidney function before starting and periodically (label). Pancreatitis, hypoglycemia with sulfonylureas or insulin. Kidney
- Kidney function before starting and periodically (dose by eGFR)
- Symptoms of pancreatitis
- Signs of heart failure in at-risk patients
- Glycemic control
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary The limited available data with JANUVIA in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy [see Clinical Considerations]. No adverse developmental effects were observed when sitagliptin was administered to pregnant rats and rabbits during organogenesis at oral doses up to 30-times and 20-times, respectively, the 100 mg clinical dose, based on AUC [see Data].
The estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a Hemoglobin A1c >7% and has been reported to be as high as 20-25% in women with a Hemoglobin A1c >10%. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, still birth, and macrosomia related morbidity.
Data Animal Data In embryo-fetal development studies, sitagliptin administered to pregnant rats and rabbits during organogenesis (gestation day 6 to 20) did not adversely affect developmental outcomes at oral doses up to 250 mg/kg (30-times the 100 mg clinical dose) and 125 mg/kg (20-times the 100 mg clinical dose), respectively, based on AUC. Higher doses in rats associated with maternal toxicity increased the incidence of rib malformations in offspring at 1000 mg/kg, or approximately 100-times the clinical dose, based on AUC.
Placental transfer of sitagliptin was observed in pregnant rats and rabbits. Sitagliptin administered to female rats from gestation day 6 to lactation day 21 caused no functional or behavioral toxicity in offspring of rats at doses up to 1000 mg/kg.
Mechanism of action
12.1 Mechanism of Action Sitagliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes mellitus by slowing the inactivation of incretin hormones. Concentrations of the active intact hormones are increased by sitagliptin, thereby increasing and prolonging the action of these hormones.
Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. These hormones are rapidly inactivated by the enzyme, DPP-4. The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis.
When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells by intracellular signaling pathways involving cyclic AMP. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production. By increasing and prolonging active incretin levels, sitagliptin increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner.
Sitagliptin demonstrates selectivity for DPP-4 and does not inhibit DPP-8 or DPP-9 activity in vitro at concentrations approximating those from therapeutic doses.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics General In patients with type 2 diabetes mellitus, administration of sitagliptin led to inhibition of DPP-4 enzyme activity for a 24-hour period. After an oral glucose load or a meal, this DPP-4 inhibition resulted in a 2- to 3-fold increase in circulating levels of active GLP-1 and GIP, decreased glucagon concentrations, and increased responsiveness of insulin release to glucose, resulting in higher C-peptide and insulin concentrations.
The rise in insulin with the decrease in glucagon was associated with lower fasting glucose concentrations and reduced glucose excursion following an oral glucose load or a meal. In studies with healthy subjects, sitagliptin did not lower blood glucose or cause hypoglycemia. Sitagliptin and Metformin hydrochloride Coadministration In a two-day study in healthy subjects, sitagliptin alone increased active GLP-1 concentrations, whereas metformin alone increased active and total GLP-1 concentrations to similar extents.
Coadministration of sitagliptin and metformin had an additive effect on active GLP-1 concentrations. Sitagliptin, but not metformin, increased active GIP concentrations. It is unclear how these findings relate to changes in glycemic control in patients with type 2 diabetes mellitus. Cardiac Electrophysiology In a randomized, placebo-controlled crossover study, 79 healthy subjects were administered a single oral dose of sitagliptin 100 mg, sitagliptin 800 mg (8 times the recommended dose), and placebo.
At the recommended dose of 100 mg, there was no effect on the QTc interval obtained at the peak plasma concentration, or at any other time during the study. Following the 800 mg dose, the maximum increase in the placebo-corrected mean change in QTc from baseline was observed at 3 hours postdose and was 8.0 msec. This increase is not considered to be clinically significant.
At the 800 mg dose, peak sitagliptin plasma concentrations were approximately 11 times higher than the peak concentrations following a 100-mg dose. In patients with type 2 diabetes mellitus administered sitagliptin 100 mg (N=81) or sitagliptin 200 mg (N=63) daily, there were no meaningful changes in QTc interval based on ECG data obtained at the time of expected peak plasma concentration.
Pharmacokinetics
Key PK parameters
| Bioavailability | About 87% |
|---|---|
| Time to peak | 1 to 4 hours |
| Half-life | About 12.4 hours |
| Half-life in kidney failure (ESKD) kidney | Not reported; AUC about 4-fold higher in severe impairment including ESRD on hemodialysis (label) |
| Volume of distribution | About 198 L (Vss) |
| Protein binding | 38% |
| Metabolism (CYP, transporters) | Minor (about 16% as metabolites); CYP3A4 with CYP2C8 |
| Active metabolites | None (trace metabolites) |
| Renal excretion kidney | About 79% unchanged in urine (active tubular secretion; OAT3, P-gp) |
| Dialyzability kidney | Modestly: about 13.5% removed over a 3- to 4-hour hemodialysis; PD removal unknown (label). |
Following a single oral 100-mg dose to healthy volunteers, mean plasma AUC of sitagliptin was 8.52 μM•hr, C max was 950 nM, and apparent terminal half-life (t 1/2 ) was 12.4 hours.
Elimination Approximately 79% of sitagliptin is excreted unchanged in the urine with metabolism being a minor pathway of elimination.
The apparent terminal t 1/2 following a 100 mg oral dose of sitagliptin was approximately 12.4 hours and renal clearance was approximately 350 mL/min.
Metabolism Following a [ 14 C]sitagliptin oral dose, approximately 16% of the radioactivity was excreted as metabolites of sitagliptin.
Excretion Following administration of an oral [ 14 C]sitagliptin dose to healthy subjects, approximately 100% of the administered radioactivity was eliminated in feces (13%) or urine (87%) within one week of dosing.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics The pharmacokinetics of sitagliptin have been extensively characterized in healthy subjects and patients with type 2 diabetes mellitus. Following a single oral 100-mg dose to healthy volunteers, mean plasma AUC of sitagliptin was 8.52 μM•hr, C max was 950 nM, and apparent terminal half-life (t 1/2) was 12.4 hours.
Plasma AUC of sitagliptin increased in a dose-proportional manner and increased approximately 14% following 100 mg doses at steady-state compared to the first dose. The intra-subject and inter-subject coefficients of variation for sitagliptin AUC were small (5.8% and 15.1%). The pharmacokinetics of sitagliptin was generally similar in healthy subjects and in patients with type 2 diabetes mellitus.
Absorption After oral administration of a 100 mg dose to healthy subjects, sitagliptin was rapidly absorbed with peak plasma concentrations (median T max) occurring 1 to 4 hours postdose. The absolute bioavailability of sitagliptin is approximately 87%. Effect of Food Coadministration of a high-fat meal with sitagliptin had no effect on the pharmacokinetics of sitagliptin.
Distribution The mean volume of distribution at steady state following a single 100-mg intravenous dose of sitagliptin to healthy subjects is approximately 198 liters. The fraction of sitagliptin reversibly bound to plasma proteins is low (38%). Elimination Approximately 79% of sitagliptin is excreted unchanged in the urine with metabolism being a minor pathway of elimination.
The apparent terminal t 1/2 following a 100 mg oral dose of sitagliptin was approximately 12.4 hours and renal clearance was approximately 350 mL/min. Metabolism Following a [14 C]sitagliptin oral dose, approximately 16% of the radioactivity was excreted as metabolites of sitagliptin. Six metabolites were detected at trace levels and are not expected to contribute to the plasma DPP-4 inhibitory activity of sitagliptin.
In vitro studies indicated that the primary enzyme responsible for the limited metabolism of sitagliptin was CYP3A4, with contribution from CYP2C8. Excretion Following administration of an oral [14 C]sitagliptin dose to healthy subjects, approximately 100% of the administered radioactivity was eliminated in feces (13%) or urine (87%) within one week of dosing.
Elimination of sitagliptin occurs primarily via renal excretion and involves active tubular secretion. Sitagliptin is a substrate for human organic anion transporter-3 (hOAT-3), which may be involved in the renal elimination of sitagliptin. The clinical relevance of hOAT-3 in sitagliptin transport has not been established.
Sitagliptin is also a substrate of P-glycoprotein (P-gp), which may also be involved in mediating the renal elimination of sitagliptin. However, cyclosporine, a P-gp inhibitor, did not reduce the renal clearance of sitagliptin. Specific Populations Patients with Renal Impairment An approximately 2-fold increase in the plasma AUC of sitagliptin was observed in patients with moderate renal impairment with eGFR of 30 to less than 45 mL/min/1.73 m², and an approximately 4-fold increase was observed in patients with severe renal impairment, including patients with ESRD on hemodialysis, as compared to normal healthy control subjects.
Patients with Hepatic Impairment In patients with moderate hepatic impairment (Child-Pugh score 7 to 9), mean AUC and C max of sitagliptin increased approximately 21% and 13%, respectively, compared to healthy matched controls following administration of a single 100-mg dose of sitagliptin. These differences are not considered to be clinically meaningful.
There is no clinical experience in patients with severe hepatic impairment (Child-Pugh score >9). Effects of Age, Body Mass Index (BMI), Gender, and Race Based on a population pharmacokinetic analysis or a composite analysis of available pharmacokinetic data, BMI, gender, and race do not have a clinically meaningful effect on the pharmacokinetics of sitagliptin.
When the effects of age on renal function are taken into account, age alone did not have a clinically meaningful impact on the pharmacokinetics of sitagliptin based on a population pharmacokinetic analysis. Elderly subjects (65 to 80 years) had approximately 19% higher plasma concentrations of sitagliptin compared to younger subjects.
Drug Interaction Studies In Vitro Assessment of Drug Interactions Sitagliptin is not an inhibitor of CYP isozymes CYP3A4, 2C8, 2C9, 2D6, 1A2, 2C19 or 2B6, and is not an inducer of CYP3A4. Sitagliptin is a P-gp substrate, but does not inhibit P-gp mediated transport of digoxin. Based on these results, sitagliptin is considered unlikely to cause interactions with other drugs that utilize these pathways.
Sitagliptin is not extensively bound to plasma proteins. Therefore, the propensity of sitagliptin to be involved in clinically meaningful drug-drug interactions mediated by plasma protein binding displacement is very low. In Vivo Assessment of Drug Interactions Effects of Sitagliptin on Other Drugs In clinical studies, sitagliptin did not meaningfully alter the pharmacokinetics of metformin, glyburide, simvastatin, rosiglitazone, digoxin, warfarin, or an oral contraceptive (ethinyl estradiol and norethindrone) (Table 4), providing in vivo evidence of a low propensity for causing drug interactions with substrates of CYP3A4, CYP2C8, CYP2C9, P-gp, and organic cationic transporter (OCT).
Table 4: Effect of Sitagliptin on Systemic Exposure of Coadministered Drugs Coadministered Drug Dose of Coadministered Drug All doses administered as single dose unless otherwise specified. Dose of Sitagliptin Geometric Mean Ratio (ratio with/without sitagliptin) No Effect = 1.00 AUC AUC is reported as AUC 0-∞ unless otherwise specified.
C max Digoxin 0.25 mg Multiple dose. once daily for 10 days 100 mg once daily for 10 days Digoxin 1.11 AUC 0-24hr. 1.18 Glyburide 1.25 mg 200 mg once daily for 6 days Glyburide 1.09 1.01 Simvastatin 20 mg 200 mg once daily for 5 days Simvastatin 0.85 AUC 0-last. 0.80 Simvastatin Acid 1.12 1.06 Rosiglitazone 4 mg 200 mg once daily for 5 days Rosiglitazone 0.98 0.99 Warfarin 30 mg single dose on day 5 200 mg once daily for 11 days S(-) Warfarin 0.95 0.89 R(+) Warfarin 0.99 0.89 Ethinyl estradiol and norethindrone 21 days once daily of 35 µg ethinyl estradiol with norethindrone 0.5 mg × 7 days, 0.75 mg × 7 days, 1.0 mg × 7 days 200 mg once daily for 21 days Ethinyl estradiol 0.99 0.97 Norethindrone 1.03 0.98 Metformin HCl 1000 mg twice daily for 14 days 50 mg twice daily for 7 days Metformin 1.02 AUC 0-12hr. 0.97 Effects of Other Drugs on Sitagliptin Clinical data described below suggest that sitagliptin is not susceptible to clinically meaningful interactions by coadministered medications (Table 5). Table 5: Effect of Coadministered Drugs on Systemic Exposure of Sitagliptin Coadministered Drug Dose of Coadministered Drug All doses administered as single dose unless otherwise specified.
Dose of Sitagliptin Geometric Mean Ratio (ratio with/without coadministered drug) No Effect = 1.00 AUC AUC is reported as AUC 0-∞ unless otherwise specified. C max Cyclosporine 600 mg once daily 100 mg once daily Sitagliptin 1.29 1.68 Metformin HCl 1000 mg Multiple dose. twice daily for 14 days 50 mg twice daily for 7 days Sitagliptin 1.02 AUC 0-12hr. 1.05
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. JANUVIA · Merck Sharp & Dohme LLC [US FDA-approved label, version 71, November 14, 2024]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f85a48d0-0407-4c50-b0fa-7673a160bf01
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- Merck Sharp & Dohme LLC. (2024). JANUVIA (sitagliptin) [Prescribing information; US FDA-approved label, NDA021995, set ID f85a48d0-0407-4c50-b0fa-7673a160bf01, version effective November 14, 2024]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f85a48d0-0407-4c50-b0fa-7673a160bf01
- Schwartz, G. J., Muñoz, A., Schneider, M. F., Mak, R. H., Kaskel, F., Warady, B. A., & Furth, S. L. (2009). New equations to estimate GFR in children with CKD. Journal of the American Society of Nephrology, 20(3), 629–637. https://doi.org/10.1681/ASN.2008030287
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026.
Last updated: .